MedTrace Logo

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

NCT00203060 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2011-04-12

No results posted yet for this study

Summary

Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.

Conditions

Interventions

DRUG

Rasagiline Mesylate

tablet, 1 or 2 mg, daily, 58 weeks

DRUG

placebo

tablet, once daily, 58 weeks

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Sheila Oren, MD · Teva Pharmaceutical Industries, Ltd.

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-07-31
Primary Completion
2000-07-31
Completion
2000-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203060 on ClinicalTrials.gov